Dendritic cell vaccination as a treatment modality for melanoma (Q37628701)

21 August 2017

1 reference

title

Dendritic cell vaccination as a treatment modality for melanoma (English)

1 reference

21 August 2017

1 reference

Jana Eubel

1

1 reference

PubMed ID

19895246

21 August 2017

Alexander H Enk

series ordinal

2

1 reference

21 August 2017

1 November 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

1631-1642

1 reference

21 August 2017

11

1 reference

Update on the incidence and mortality from melanoma in the United States.

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Recent trends in incidence of cutaneous melanoma among US Caucasian young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Trends in sunburns, sun protection practices, and attitudes toward sun exposure protection and tanning among US adolescents, 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Indoor tanning by adolescents: prevalence, practices and policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Light during darkness and cancer: relationships in circadian photoreception and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Melanoma and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Adjuvant therapy of melanoma with interferon: lessons of the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Taking dendritic cells into medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Expression of C-type lectin receptors by subsets of dendritic cells in human skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Developmental regulation of MHC class II transport in mouse dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

CD83 on dendritic cells: more than just a marker for maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Immunology. Licence to kill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Update on non-acquired immunodeficiency syndrome-defining malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Development of a Langerhans cell phenotype from peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Evaluation of in vivo labelled dendritic cell migration in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Analysis of human transcriptomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Chromosome alignment and segregation regulated by ubiquitination of survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Immature, but not inactive: the tolerogenic function of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Clinical trials with tumor antigen genetically modified dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

The tumor microenvironment and its role in promoting tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.139

21 January 2018

Identifiers

DOI

10.1586/ERA.09.139

1 reference

21 August 2017

1 reference

PubMed ID

19895246